MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

ABSTRACT: This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

DISEASE(S): Recurrent Childhood Small Noncleaved Cell Lymphoma,Lymphoma, Large B-cell, Diffuse,Blastic Phase Chronic Myelogenous Leukemia,Myeloproliferative Disorders,Lymphoma, Large-cell, Immunoblastic,Lymphoproliferative Disorders,Leukemia, Myeloid, Chronic-phase,Leukemia, Neutrophilic, Chronic,Recurrent Childhood Anaplastic Large Cell Lymphoma,Small Intestine Lymphoma,Progressive Hairy Cell Leukemia, Initial Treatment,Childhood Burkitt Lymphoma,Recurrent Grade 1 Follicular Lymphoma,Refractory Hairy Cell Leukemia,Sezary Syndrome,Secondary Acute Myeloid Leukemia,Splenic Marginal Zone Lymphoma,Leukemia, Hairy Cell,Childhood Immunoblastic Large Cell Lymphoma,Refractory Chronic Lymphocytic Leukemia,Mycosis Fungoides,Lymphoma, Mantle-cell,Recurrent Childhood Acute Myeloid Leukemia,Juvenile Myelomonocytic Leukemia,Lymphomatoid Granulomatosis,Leukemia, Myelomonocytic, Acute,Primary Central Nervous System Non-hodgkin Lymphoma,Recurrent Childhood Lymphoblastic Lymphoma,Leukemia, Mast-cell,Acute Disease,Lymphoma, Extranodal Nk-t-cell,Plasmablastic Lymphoma,Lymphoma, B-cell, Marginal Zone,Burkitt Lymphoma,Leukemia, Myelogenous, Chronic, Bcr-abl Positive,Chronic Myelomonocytic Leukemia,Acute Undifferentiated Leukemia,Post-transplant Lymphoproliferative Disorder,Acute Leukemias Of Ambiguous Lineage,Aggressive Nk-cell Leukemia,Childhood Diffuse Large Cell Lymphoma,Recurrent Small Lymphocytic Lymphoma,Recurrent Marginal Zone Lymphoma,Lymphoma, Follicular,Waldenstrom Macroglobulinemia,Leukemia, Myeloid, Accelerated Phase,Acute Myeloid Leukemia/transient Myeloproliferative Disorder,Leukemia, Lymphocytic, Chronic, B-cell,Intraocular Lymphoma,Recurrent Mantle Cell Lymphoma,Relapsing Chronic Myelogenous Leukemia,Unspecified Childhood Solid Tumor, Protocol Specific,Chronic Phase Chronic Myelogenous Leukemia,Recurrent Childhood Acute Lymphoblastic Leukemia,Recurrent Grade 3 Follicular Lymphoma,Childhood Chronic Myelogenous Leukemia,Hypereosinophilic Syndrome,Leukemia,Hodgkin Disease,Primary Central Nervous System Hodgkin Lymphoma,Accelerated Phase Chronic Myelogenous Leukemia,Mycoses,Childhood Grade Iii Lymphomatoid Granulomatosis,Waldenström Macroglobulinemia,Noncutaneous Extranodal Lymphoma,Recurrent Childhood Large Cell Lymphoma,Recurrent Childhood Grade Iii Lymphomatoid Granulomatosis,Leukemia, Myeloid, Acute,Leukemia, Myelomonocytic, Chronic,Blastic Plasmacytoid Dendritic Cell Neoplasm,Leukemia, Large Granular Lymphocytic,Lymphoma, Large-cell, Anaplastic,Atypical Chronic Myeloid Leukemia, Bcr-abl1 Negative,Blast Crisis,Leukemia, Myelomonocytic, Juvenile,Leukemia, Myeloid,Prolymphocytic Leukemia,Leukemia, Prolymphocytic,Precursor Cell Lymphoblastic Leukemia-lymphoma,Lymphoma,Childhood Nasal Type Extranodal Nk/t-cell Lymphoma,Recurrent Mycosis Fungoides/sezary Syndrome,Leukemia, Myeloid, Chronic, Atypical, Bcr-abl Negative,Myeloid/nk-cell Acute Leukemia,Chronic Eosinophilic Leukemia,Recurrent Grade 2 Follicular Lymphoma,Lymphoma, Non-hodgkin,Chronic Neutrophilic Leukemia,Mast Cell Leukemia,Recurrent/refractory Childhood Hodgkin Lymphoma

PROVIDER: 2097388 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR